Incyte has the cash and two years to replace Jakafi

The technology

Incyte sells JAK inhibitors, drugs that block signaling enzymes involved in blood cancers and immune disease. Its anchor is Jakafi (ruxolitinib), which treats myelofibrosis, polycythemia vera and graft-versus-host disease. Opzelura is a cream version approved for skin conditions including vitiligo. Povorcitinib is a newer oral JAK inhibitor, in a filed NDA for hidradenitis suppurativa and phase 3 trials in vitiligo and prurigo nodularis.

Beyond JAKs, Incyte is building a hematology and oncology pipeline: an antibody against mutant calreticulin (INCA033989) in phase 3 for essential thrombocythemia, a KRAS G12D inhibitor in phase 3 for first-line pancreatic cancer, and latarcibart, acquired from Vega, for von Willebrand disease. It has also signed AI partnerships with Genesis Molecular AI and Edison Scientific.

The odds

Several decisions are near. Povorcitinib in hidradenitis suppurativa has an accepted NDA and Incyte expects a U.S. approval in the first quarter of 2027. The BIO/Informa/QLS base rates show that 90.6% of filed applications reach approval. The company also expects U.S. approval of Monjuvi in newly diagnosed lymphoma in the first quarter of 2027, after the frontMIND phase 3 met its primary endpoint.

The harder bets are earlier. The mutCALR antibody started phase 3 in mid-2026, so it still faces the BIO/Informa/QLS base rate of 57.8% of phase 3 programs reaching a filing. Vitiligo data for povorcitinib were positive but trail Rinvoq's placebo-adjusted results, per Fierce Biotech.

The money

Incyte is profitable. Second-quarter total revenue was $1.67 billion, up 38%, with net income of $585.6 million on a GAAP basis. Without a one-time $246 million Opzelura benefit from a CMS settlement, net sales grew 17%. Cash and securities were $4.5 billion at June 30.

The company raised 2026 net sales guidance to $5,130 million to $5,260 million. It will take a charge of about $1.27 billion in the third quarter for the Vega acquisition, which cost $1.25 billion upfront plus up to $750 million in sales milestones. GAAP spending guidance rose accordingly.

The risks

The first risk is Jakafi. It made 71% of Incyte's nearly $4.4 billion in net product revenue last year and loses exclusivity between late 2028 and early 2029. Jakafi XR, approved in May, is the company's first mitigation, but it targets only 3% to 5% of patients.

The second is policy. Opzelura's sales depend on a CMS settlement, and CEO Bill Meury says the pricing and reimbursement environment is dynamic. The third is competition: AbbVie's Rinvoq is filed in vitiligo with stronger placebo-adjusted results, and Opzelura's underlying growth was 24% in the quarter, less than the headline. The fourth is execution across a pipeline of ten phase 3 studies.

Our read

Incyte is a profitable company trying to turn one dominant drug into a diversified one before the patents run out. The most important numbers in the quarter were the underlying ones: 17% net sales growth, Jakafi up 7%, Opzelura up 24% before the settlement benefit.

The strategy has been to buy and partner, with Vega, Genesis and Edison all announced within a few weeks, and to fund it from Jakafi cash. That works if the pipeline produces replacement revenue by 2029. The checkpoints are the first-quarter 2027 decisions on povorcitinib and Monjuvi, the fourth-quarter data in hidradenitis suppurativa and prurigo nodularis, and the October ESMO presentations. Each can move the story, and none by itself replaces Jakafi's $3.2 billion.